|
Status |
Public on May 02, 2019 |
Title |
Subject 101003 at Week 0,lesional |
Sample type |
RNA |
|
|
Source name |
homo sapiens skin biopsy, Week 0, lesional
|
Organism |
Homo sapiens |
Characteristics |
Sex: M time: Week0 tissue: LS treatment: Dupilumab subject id: 101003 race: ASIAN ethnicity: NOT HISPANIC OR LATINO easi: 49.2 scorad: 78.9
|
Treatment protocol |
Atopic dermatitis patients randomized 1:1 to dupilumab 200mg or placebo weekly for 16 weeks, with lesional and non-lesional biopsies taken at baseline, week 4 (only lesional) and week 16 both lesional and non lesional
|
Growth protocol |
n/a
|
Extracted molecule |
total RNA |
Extraction protocol |
RNA was extracted according to manufacturer's instructions.
|
Label |
biotin
|
Label protocol |
n/a
|
|
|
Hybridization protocol |
RNA was hybridized to Affymetrix Human U133Plus 2.0 gene arrays
|
Scan protocol |
n/a
|
Description |
gene expression data from lesional and non-lesional skin phenotypes of patients with moderate-to-severe atopic dermatitis
|
Data processing |
Expression measures were obtained by using the GC Robust Multi-array Average algorithm.
|
|
|
Submission date |
May 01, 2019 |
Last update date |
Oct 01, 2019 |
Contact name |
Mayte Suarez-Farinas |
E-mail(s) |
mayte.suarezfarinas@mssm.edu
|
Organization name |
Mount SinaiSchool of Medicine
|
Street address |
1425 Madison Ave, L2-70C, Box 1077,
|
City |
New York |
State/province |
NY |
ZIP/Postal code |
10075 |
Country |
USA |
|
|
Platform ID |
GPL570 |
Series (1) |
GSE130588 |
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis |
|